Eli Lilly and Company
Every calculator, already run for LLY
Open the full toolkit →You have the numbers on LLY. Get the argument.
A written report on which of these readings actually decide the outcome for Eli Lilly and Company, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
30 analysts covering LLYAnalyst Price Target Disagreement for Eli Lilly and Company
Wall Street's bull case implies +43% from the current price; the bear case implies -17%. A 60% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for LLY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for color…
LLY — frequently asked
Is LLY a buy right now?
Wall Street's consensus rating on Eli Lilly and Company is Buy across 30 analysts, with a mean price target of $1,318.66 (+18% vs. the current $1,115.70). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is LLY overvalued?
LLY trades at 37.5x trailing earnings, against a DCF fair value of $403 per share. The current price implies 19% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is LLY's next earnings date?
Eli Lilly and Company is next scheduled to report earnings around Oct 29, 2026. A full LLY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Eli Lilly and Company?
Analysts covering Eli Lilly and Company (LLY) range from a bear-case target of $930.00 to a bull-case high of $1,600.00, with a mean consensus target of $1,318.66 across 29 analysts. The spread of $670.00 (60% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Eli Lilly and Company against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Eli Lilly and Company
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full LLY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Eli Lilly and Company, in minutes. 3 free reports included with every account — no credit card required.